Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
25.90    0.00 (0.00%)
Bid:
26.00
Ask:
26.90
Spread: 0.90 (3.462%)
Market Cap: £111.44m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Half-yearly Report

4 Aug 2008 07:00

Embargoed Release: 07:00hrs Monday 4 August 2008

INTERNATIONAL BRAND LICENSING PLC ("IBL", the "Group" or the "Company") INTERIM REPORT FOR THE SIX MONTHS TO 30 JUNE 2008

International Brand Licensing plc, the branded sports lifestyle company, announces its interim results for the period ended 30 June 2008.

CHAIRMAN'S STATEMENT

During the first six months of the year Group revenue decreased to ‚£306,000 (2007: ‚£1,534,000), and there was an operating loss before exceptional items of ‚£171,000 (2007: profit of ‚£204,000). The sale of trademarks in Turkey generated ‚£317,000 of exceptional profit in the first six months of 2008 which, coupled with a share based payment expense of ‚£30,000 and interest received of ‚£32,000, resulted in profit before tax of ‚£148,000 (2007: ‚£1,228,000).

The major reduction in revenues and profits reflects the impact of our decision to withdraw from the England cricket sponsorship agreement one year early on 31 March 2008. Considering the extremely depressed sports retail market of today and the decline in demand for replica merchandise, it was undoubtedly the right decision for the Company.

Given the significant change in the business model a direct comparison of the two years is rather meaningless, and it is much more relevant to focus on the future and the opportunities the Company has. Having withdrawn from the capital intensive and high risk sports supply business, the Company has emerged as a streamlined intellectual property and licensing business.

With the Admiral brand we have the combined opportunities of liquidating selected markets in return for cash, and the signing of new licensee partners in lucrative unexploited markets. We are presently engaged in negotiations on both fronts and expect to make further announcements in the coming months.

Since the period end, the Company announced the sale of its Admiral sportswear trademarks in southern Africa for a cash consideration of ‚£225,000. This has strengthened our balance sheet even further by liquidating largely unproductive assets in return for cash.

With regards to Muscle Athletic, the fitness brand which we acquired in 2006, we are presently in negotiation with a number of proven Admiral licensees interested in distributing this exciting new brand in their markets, plus a number of other candidate partners. A key element of growing our licensing business is that costs do not rise proportionately to revenues and most of the incremental royalty of new agreements adds directly to Group profit.

Your Board will continue to pursue opportunities to add value to the Company from both a corporate and licensing perspective and we remain very confident in the future prospects of the business.

Adam ReynoldsChairman4th August 2008

For further information please contact:

International Brand Licensing Plc

Paul Foulger +44 (0) 20 7245 1100

Blue Oar Securities Plc

William Vandyk +44 (0) 20 7448 4400

CONSOLIDATED INCOME STATEMENT

FOR THE PERIODENDED 30 JUNE 2008

Six months Six months Year to to 30 June to 30 June 31 December 2008 2007 2007 Notes Unaudited Unaudited Audited ‚£000 ‚£000 ‚£000 Group revenue 4 306 1,534 1,857 Cost of sales (24) (669) (1,012) _________ _________ _________ GROSS PROFIT 282 865 845 Administrative expenses (453) (661) (1,364) _________ _________ _________ OPERATING (LOSS)/PROFIT (171) 204 (519)BEFORE EXCEPTIONAL ITEMS Exceptional profit on sale 317 1,046 1,152of intangible assets Share based payments (30) (30) (61) _________ _________ _________ OPERATINGPROFITAFTER 116 1,220 572EXCEPTIONAL ITEMS Finance income 32 16 50 Finance costs - (8) (7) _________ _________ _________ PROFIT BEFORE TAXATION 148 1,228 615 Taxation (36) (296) (150) _________ _________ _________ PROFIT FOR THE PERIOD 112 932 465ATTRIBUTABLE TO EQUITY HOLDERS _________ _________ _________ Earnings per share Basic and diluted 5 0.34p 2.8p 1.4p _______ ________ ________

CONSOLIDATED STATEMENT OF RECOGNISED INCOME AND EXPENSES

FOR THE PERIOD ENDED 30 JUNE 2008

At 30 At 30 At 31 June June December 2008 2007 2007 Unaudited Unaudited Audited ‚£000 ‚£000 ‚£000 Profit for the period 112 932 465 Exchange differences on translation 132 (118) 224of foreign operations Fair value adjustment in respect of - - (43)available-for-sale financial assets _______ _______ _______ Total recognised income and expenses 244 814 646for the period attributableto equity shareholders ________ ________ ________CONSOLIDATED BALANCE SHEETAS AT 30 JUNE 2008 Six months Six months Year to 31 to 30 June to 30 June December 2008 2007 2007 Notes Unaudited Unaudited Audited ‚£000 ‚£000 ‚£000 Assets Non-current assets Property, plant and equipment 6 8 6 Intangibles 2 3,498 2,814 3,365 Deferred tax assets 50 - 50 Available-for-sale financial 70 - 70assets ________ ________ ________ Total non-current assets 3,624 2,822 3,491 ________ ________ ________ Current Assets Inventories 90 614 110 Trade and other receivables 619 1,534 527 Cash and cash equivalents 1,341 1,255 1,437 ________ ________ ________ Total current assets 2,050 3,403 2,074 ________ ________ ________ Total assets 5,674 6,225 5,565 _______ _______ _______ Liabilities Current Liabilities Trade and other payables (356) (1,112) (491) Current tax liabilities (98) - (98) ________ ________ ________ Total current liabilities (454) (1,112) (589) ________ ________ ________ Net assets 5,220 5,113 4,976 ________ ________ ________ Equity Issued share capital 336 336 336 Share premium account 3,090 3,090 3,090 Other reserve 244 244 244 Foreign currency reserves 195 (118) 63 Retained Earnings 1,355 1,561 1,243 _______ _______ _______ Total Shareholders' Equity 5,220 5,113 4,976 ________ ________ ________

CONSOLIDATED CASH FLOW STATEMENT

FOR THE PERIOD ENDED 30 JUNE 2008

Six months Six months Year to 31 ended 30 ended 30 December June 2008 June 2007 2007 Unaudited Unaudited Audited ‚£000 ‚£000 ‚£000 Operating activities Operating profit after exceptional items 116 1,220 572 Depreciation - 1 3

Exceptional profit on sale of intangible (317) (1,496) (1,152) asset

(Increase)/decrease in receivables (92) (157) 812 Increase/(decrease) in payables (136) 129 (77) (Increase)/decrease in inventories 20 (22) 483 Gain/(loss) on exchange - (118) - Share-based payment 30 30 61 Taxes paid (66) (11) (118) ________ ________ ________ Net cash(used in) / generated by operating (445) (424) 584activities ________ ________ ________ Investing Activities Interest received 32 16 50 Diminution in value of intangible asset - 300 - Net proceeds on sale of intangible asset 317 1,600 1,152 Purchase of listed investments - - (113) ________ ________ ________

Net cash generated by investing activities 349 1,916 1,089

________ ________ ________ Financing Activities Interest paid - (8) (7) ________ ________ ________ Net cash used in financing activities - (8) (7) ________ ________ ________ Net (decrease)/increasein cash and cash (96) 1,484 1,666equivalents

Cash and cash equivalents at beginning of 1,437 (229) (229) period

________ ________ ________

Cash and cash equivalents at end of period 1,341 1,255 1,437

________ ________ ________

STATEMENT OF CHANGES IN EQUITY

FOR THE PERIOD ENDED 30 JUNE 2008

Share Share Other Foreign Retained Total Reserve Currency earnings equity Capital Premium Reserve ‚£000 ‚£000 ‚£000 ‚£'000 ‚£000 ‚£000 At 1 January 2007 336 3,090 244 (161) 790 4,299 Profit for the - - - - 465 465year Fair value - - - - (43) (43)adjustment in respect of available-for-sale financial assets Equity-settled - - - - 31 31share based payment Exchange - - - 224 - 224Difference _______ ________ ________ ________ ________ ________ At 1 January 2008 336 3,090 244 63 1,243 4,976 Profit for the - - - - 112 112period Exchange - - - 132 - 132Difference _______ ________ ________ ________ ________ ________ At 30 June 2008 336 3,090 244 195 1,355 5,220 _______ _______ _______ ________ ________ ________

NOTES FORMING PART OF THE INTERIM FINANCIAL STATEMENTS

1.Basis of preparation of the financial statements

The interim accounts have been prepared in accordance with International Financial Reporting Standards (IFRS and IFRIC Interpretations) issued by the International Accounting Standards Board (IASB) as adopted by the European Union and with those parts of the Companies Acts applicable to Companies preparing financial statements under IFRS.

The interim results do not constitute statutory results within the meaning of section 240 of the Companies Act 1985. The interim results to 30 June 2008 are neither audited nor reviewed by the auditors. The financial information for the full preceding year is based on the statutory accounts for the year ended 31 December 2007, upon which the auditors issued an unqualified opinion and which have been filed with the Registrar of Companies.

This interim report does not comply with IAS 34 "Interim Financial Reporting", as is currently permissible under the rules on the Alternative Investment Market ("AIM").

2. Intangible assets

Intangible assets represent acquired trademarks and are recorded at historic cost. No amortisation is charged as they are regarded as having infinite lives. The annual results reflect the expenditure incurred in the support and development of these brands. In addition, the trademarks are supported by the existence of international licensee agreements, which establish obligations as to guaranteed minimum licence income and marketing arrangements with the view to maximising long-term growth. The directors believe that the licence agreements will be renewed at the end of their legal expiry dates and that the value of the trademarks will be maintained. The carrying values are reviewed annually and written down to the estimated recoverable amount as necessary.

3. Share-based payment

The group operates share incentive and option schemes for directors and employees. For all share awards the fair value as at the date of grant is calculated using an option pricing model and the charge to profit and loss account is recognised as a staff cost over the vesting period.

4. Revenue Six months to Six months to Year to 31 30 June 2008 30 June 2007 December 2007 Unaudited Unaudited Audited ‚£000 ‚£000 ‚£000 Licensing 306 280 341 Replica Kit (24) 1,254 1,516 ________ ________ _______ Total 282 1,534 1,857 ________ ________ ________5. Earnings per shareThe basic earnings per share is calculated by dividing the profit for thefinancial year attributable to shareholders by the weighted average number ofshares in issue. Six months Six months Year to 31 to 30 June to 30 June December 2008 2007 2007 Weighted average number of shares 33,593,353 33,593,353 33,593,353 Dilutive effect of share options - 40,500 - ________ ________ ________

Diluted weighted average ordinary shares 33,593,353 33,633,853 33,593,353

________ ________ ________ Profit for the period ‚£000 ‚£000 ‚£000 112 932 465 ________ ________ ________ Basic and diluted earnings per 1p Pence Pence Penceordinary share 0.34 2.8 1.4 ________ ________ ________ 6. Dividends

There were no dividends provided or paid during the six months.

vendor
Date   Source Headline
11th Oct 20184:01 pmRNSFundraising and AIM admission of Renalytix AI plc
27th Sep 201810:15 amRNSNotice of GM
19th Sep 20187:00 amRNSHalf-year Report
17th Sep 201812:21 pmRNSNotice of Results
31st Aug 20182:00 pmRNSUpdate regarding proposed IPO of Renalytix AI
16th Aug 20187:00 amRNSHolding(s) in Company
9th Aug 20187:14 amRNSTrading update
9th Aug 20187:00 amRNSDiaSpect Tm McKesson US distribution agreement
8th Aug 20184:09 pmRNSHolding(s) in Company
24th Jul 20188:45 amRNSUS distribution agreement for diabetes assay kit
19th Jul 20187:00 amRNSManufacturing partnership with Oragenics, Inc.
4th Jul 20183:15 pmRNSExploring funding options for Renalytix AI
7th Jun 20182:30 pmRNSHolding(s) in Company
1st Jun 201810:00 amRNSUpdate regarding Renalytix AI PLC
31st May 20187:00 amRNSLicence and collaboration agreement signed
8th May 20183:10 pmRNSResult of AGM
18th Apr 201810:36 amRNSPosting of AR and Accounts & Notice of AGM
9th Apr 20188:25 amRNSUS FDA approval for Diaspect Tm
21st Mar 20182:18 pmRNSHolding(s) in Company
14th Mar 20187:00 amRNSFinal Results
21st Feb 20187:00 amRNSNotice of Results
11th Jan 20187:00 amRNSTrading update
29th Dec 20177:00 amRNSTotal Voting Rights
21st Dec 20177:00 amRNSShare cancellation
1st Dec 20177:00 amRNSTotal Voting Rights
7th Nov 20173:07 pmRNSHolding(s) in Company
2nd Nov 20179:18 amRNSConfirmation of share cancellation
1st Nov 20177:00 amRNSTotal Voting Rights
27th Oct 20175:05 pmRNSHolding(s) in Company
3rd Oct 20173:44 pmRNSCancellation of escrow shares PDMR dealing/buyback
21st Sep 201710:16 amRNSHolding(s) in Company
11th Sep 20177:00 amRNSHalf-year Report
6th Sep 20171:41 pmRNSReduction of capital
31st Aug 20177:00 amRNSNotice of Results
10th Aug 20177:00 amRNSHolding(s) in Company
7th Aug 20179:45 amRNSHolding(s) in Company
27th Jul 201711:18 amRNSResult of General Meeting
19th Jul 20178:54 amRNSHolding(s) in Company
6th Jul 20177:00 amRNSTrading update
26th Jun 20177:00 amRNSNotice of GM
26th Jun 20177:00 amRNSCancellation of share options
10th May 201711:45 amRNSResult of AGM
10th May 20177:00 amRNSTrading Update & Structure Update
18th Apr 201712:00 pmRNSAnnual Financial Report
4th Apr 201710:55 amRNSHolding(s) in Company
21st Mar 20171:47 pmRNSDirector/PDMR Shareholding
21st Mar 201712:04 pmRNSHolding(s) in Company
20th Mar 20177:00 amRNSFinal Results
20th Mar 20177:00 amRNSUpdate
2nd Mar 20177:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.